Pergunte ou pesquise qualquer coisa...
Hot Research Today
Papers from every journal, all in one place. Crie feeds personalizados.
RCT · n=1,4657 mençõesTrending on X
22 DE JUL.Machline-CarrionJAMA Cardiology
Digital quality improvement reduces 6-month LDL-C by ~7 mg/dL compared to routine practice.
Supports adoption of digitally enabled QI for LDL-C reduction in routine care; extends RCT evidence for technology-assisted lipid management.
MJM. Julia Machline-Carrion, et al.
Cardiology Researchers, epHealth UK, Scale Space, Imperial College White City Campus
In this cluster randomized clinical trial, a digitally enabled, multifaceted QI intervention embedded within routine clinical care modestly improved LDL-C control and increased use of intensive and combination [lipid-lowering therapy] among patients with established ASCVD. These findings add incremental evidence that a digitally enabled QI strategy can contribute to bridging evidence-practice gaps in secondary cardiovascular prevention and complement pharmacological advances in real-world settings, although the partial effectiveness of the present strategy indicates that further refinement of implementation strategies and digitally enabled delivery methods is needed to fully close the residual care gap.
RCT · n=4556 mençõesTrending on X
24 DE JUL.RiihiniemiCirculation Cardiovascular Interventions
PCI reduces MACE ~47% in TAVI patients with ≥90% coronary stenosis but not <90% stenosis.
PCI benefit in TAVI patients appears confined to severe proximal stenoses; extends NOTION-3 by refining lesion selection for revascularization.
cohort · n=1,1226 mençõesTrending on X
22 DE JUL.SteinJACC Advances
T-TEER is linked to ~83% fewer procedural complications than TTVA but similar 1-year major events.
Comparative outcomes of T-TEER versus TTVA remain limited; leaves open optimal repair strategy in secondary TR.
systematic_review
23 DE JUL.JamilehJACC Advances
CV screening in LMICs detects hypertension in ~55% of individuals despite weak linkage to care.
Screening detects high cardiometabolic burden in LMICs but weak linkage limits impact; extends evidence on implementation gaps needing integrated pathways.
cohort · n=105
22 DE JUL.GénéreuxJAMA Cardiology
Positive TST in asymptomatic severe AS is safe and predicts ~86% 2-year AVR rate.
TST may refine AS risk stratification in screening; leaves open whether routine use improves outcomes in asymptomatic severe AS.
cohort · n=8,6874 mençõesTrending on X
23 DE JUL.Al‐AbchaJACC Advances
Moderate degenerative MR shows similar adjusted mortality risk to functional MR despite higher unadjusted survival.
Moderate MR shows similar adjusted mortality by etiology; leaves open whether phenotype-specific strategies improve outcomes.
cohort · n=3201 mençõesTrending on X
23 DE JUL.MiyamaJournal of Cardiovascular Electrophysiology
PFA yields similar 1-year freedom from atrial arrhythmia recurrence as RFA for repeat AF ablation.
PFA may offer a feasible option for repeat AF ablation; leaves open comparative efficacy versus RFA in randomized trials.
meta-analysis4 mençõesTrending on X
23 DE JUL.BachaCardiology in Review
Adding antiplatelet therapy to DOACs fails to reduce recurrent stroke but increases major bleeding ~43%.
Avoid dual antithrombotic therapy in AF with atherosclerotic disease due to excess bleeding without efficacy gain; leaves open need for dedicated RCTs.
meta-analysis · n=131,7281 mençõesTrending on X
23 DE JUL.KhanUniversity of Lahore
Watchman FLX linked to ~2% higher procedural success, less bleeding, stroke, and mortality vs Watchman 2.5.
Supports FLX preference for LAAO in anticoagulation-intolerant AF; extends head-to-head evidence for device selection.
cohort · n=342 mençõesTrending on X
23 DE JUL.KidoJACC Advances
Community pharmacist collaborative care for HF yields clinical interventions with a ~38% acceptance rate.
May support pharmacist-HF partnerships in pilots; leaves open scalability and outcome impact.
DKDr. Kazuhiko Kido
Pharm.D., Ph.D., clinical associate professor of Clinical Pharmacy and heart failure pharmacist, WVU School of Pharmacy and WVU Heart and Vascular Institute
Recent statewide data show underutilization of life-saving heart failure medications in West Virginia. To address this, we are developing a Community Pharmacy Heart Failure Certificate Program and Statewide Collaborative Network to improve health disparities in local heart failure care. This Program will help pharmacies work closely with local doctors to ensure patients get the best treatment, stay on their medications, and reduce hospital visits.